Zenas BioPharma, Inc. Zenas BioPharma, Inc.

Zenas BioPharma, Inc.

ZBIO

Rank in Stocks #6071
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm,... Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
Share Price
$28.01
Last synced: 2026-11-13
Market Cap
$1.85B
Change (1 day)
1.34%
Change (1 year)
-19.60%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
Operating Margin for Zenas BioPharma, Inc. (ZBIO)
Operating Margin as of November 2026 TTM: -4,785.47%
According to Zenas BioPharma, Inc.'s latest financial reports, its current operating margin (TTM) is -4,785.47%. At the end of 2025 the company had an operating margin of -2,113.85%.
Operating Margin history for Zenas BioPharma, Inc. from 2022 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) -4,785.47% 126.39%
2025 -2,113.85% -35.51%
2024 -3,277.76% 4,312.11%
2023 -74.29% 0.00%
2022 0.00% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
-195.39% -99.96%
US
33.87% -100.01%
US
-116.04% -99.98%
US
25.57% -100.01%
AU
31.23% -100.01%
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.

Questions about Zenas BioPharma, Inc.'s operating margin

What is Zenas BioPharma, Inc.'s operating margin?

Zenas BioPharma, Inc.'s operating margin is -4,785.47%, as of Nov 2026.

What was Zenas BioPharma, Inc.'s operating margin in 2025?

In 2025, Zenas BioPharma, Inc.'s operating margin was -2,113.85%, compared with -3,277.76% in 2024.

How has Zenas BioPharma, Inc.'s operating margin changed since 2022?

From 2022 to 2025, Zenas BioPharma, Inc.'s operating margin was highest in 2022 (0.00%) and lowest in 2024 (-3,277.76%).

How does Zenas BioPharma, Inc.'s operating margin compare with similar companies?

Zenas BioPharma, Inc.'s operating margin (-4,785.47%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.